brand logo

Am Fam Physician. 2020;102(12):756-757

Author disclosure: No relevant financial affiliations.

Lasmiditan (Reyvow) is a 5-HT1F receptor agonist labeled for the treatment of acute migraine with or without aura in adults.

DrugDosageDose formCost*
Lasmiditan (Reyvow)50 mg, 100 mg, or 200 mg taken once in a 24-hour period as neededTablet$83 per tablet

Safety

Lasmiditan may cause impairment and sleepiness due to central nervous system depression. Patients should be advised not to drive for at least eight hours after taking lasmiditan, or longer if they still feel impaired. Combining the medication with other central nervous system depressive agents requires caution.1 Less common severe adverse effects include serotonin syndrome, which occurred in two out of 4,878 patients in initial trials, and bradycardia (average reduction of 10 beats per minute), which was more pronounced in combination with propranolol (average reduction of 19 beats per minute).1,2 Some patients (about 1%) may experience hallucinations or euphoria, and there is a potential for abuse; as a result, lasmiditan is a controlled substance (schedule V).1 Lasmiditan has not been studied in pregnant or breastfeeding patients.

Tolerability

The most common adverse effects include dizziness (up to 15%), paresthesia (up to 9%), somnolence (up to 7%), and fatigue (up to 6%), which are dose-dependent and appear to decrease with subsequent use.2 Dizziness was more common in patients older than 65 years.1 Over three to 12 months of study, about 11% to 14% of patients discontinued lasmiditan because of adverse effects, with higher rates of discontinuation at higher doses.1

Effectiveness

In two studies that included a total of 3,981 patients 18 years and older with a history of three to eight migraine attacks per month, a significantly greater number of patients were pain free two hours after taking lasmiditan vs. placebo (30% to 36% vs. 20%, respectively; number needed to treat [NNT] = 6 to 10).3 These two studies also evaluated the effectiveness of lasmiditan for acute treatment of migraine attack in patients taking daily preventive medication (n = 698). In these patients, all three dosages of lasmiditan produced a significantly higher number who were pain free at two hours compared with placebo (24% to 30% vs. 12%, respectively; NNT = 5 to 8).3 In patients who do not respond to the initial dose, a second dose does not provide additional likelihood of benefit compared with placebo.4

In a study of 1,978 patients with severe migraine-related disability receiving a daily preventive treatment, about one-half experienced a 50% reduction in disability scores over 12 months of treatment with lasmiditan as needed.5 Lasmiditan has not been studied as a preventive treatment for migraine. The effectiveness of lasmiditan has not been compared with other acute migraine treatments.

Price

Lasmiditan costs approximately $83 per tablet. This is significantly more expensive than many other oral migraine abortive treatments.

Simplicity

Lasmiditan should be taken as a single dose of 50 mg, 100 mg, or 200 mg per day as needed. The manufacturer does not specify a starting dose, but response rates have been shown to be similar with all doses. Dosing should not be repeated within 24 hours, and patients should not drive for eight hours after taking a dose.

Bottom Line

Lasmiditan is a costly alternative to other more extensively studied medications for acute migraine. It should be reserved for those patients who lack relief with other available agents or who cannot tolerate other abortive medications.

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2020 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.